Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab +/- HLX04 + Chemo in 1L Non-Squamous NSCLC
NCT03952403Phase 3Unknown
- Sponsor
- Henlius
- Start
- Dec 2019
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of serplulimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (4 arms), sponsored by Henlius. Primary endpoints: Part 1 Safety and tolerability of study treatment at 21 days and Part 2-Progression Free Survival (PFS) as Determined by the IRRC up to 24 months. Status: unknown.
02
Drugs
serplulimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03952403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952403.